GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » Operating Margin %

Corix Bioscience (Corix Bioscience) Operating Margin % : 0.00% (As of Sep. 2017)


View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Corix Bioscience's Operating Income for the three months ended in Sep. 2017 was $-0.30 Mil. Corix Bioscience's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, Corix Bioscience's Operating Margin % for the quarter that ended in Sep. 2017 was 0.00%.

The historical rank and industry rank for Corix Bioscience's Operating Margin % or its related term are showing as below:


CXBS's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.08
* Ranked among companies with meaningful Operating Margin % only.

Corix Bioscience's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Corix Bioscience's Operating Income for the three months ended in Sep. 2017 was $-0.30 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 was $-4.01 Mil.


Corix Bioscience Operating Margin % Historical Data

The historical data trend for Corix Bioscience's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corix Bioscience Operating Margin % Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Operating Margin %
Get a 7-Day Free Trial - - - - -555.33

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corix Bioscience's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corix Bioscience's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Operating Margin % falls into.



Corix Bioscience Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Corix Bioscience's Operating Margin % for the fiscal year that ended in Dec. 2016 is calculated as

Operating Margin %=Operating Income (A: Dec. 2016 ) / Revenue (A: Dec. 2016 )
=-3.854 / 0.694
=-555.33 %

Corix Bioscience's Operating Margin % for the quarter that ended in Sep. 2017 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2017 ) / Revenue (Q: Sep. 2017 )
=-0.3 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corix Bioscience  (GREY:CXBS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Corix Bioscience Operating Margin % Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Corix Bioscience (Corix Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines